ArticleJournal of ovarian research2025
Carvacrol ameliorates cyclophosphamide-induced rat premature ovarian failure and uterine fibrosis via regulating PI3K/AKT/FOXO3a signaling pathway.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Antioxidant and anti-apoptotic effects of curcumin-loaded nanoliposomes against di-n-butyl phthalate-induced hepatorenal damage in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A Two-Hit Hypothesis for Chemotherapy-Induced Primary Ovarian Insufficiency in Asian Populations: A Population-Specific Mechanistic Framework Linking Genetic Susceptibility and Cytotoxic Stress via the PI3K-AKT-FOXO3 Axis.BioMed research international · 2026Review
- Comparative effects of dietary pomegranate peel andFrontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPremature ovarian failure (POF) and ovarian reserve loss are common problems associated with cancer therapies. Carvacrol (Carva) showed significant efficacies in ameliorating several toxicological impacts and complications associated with chemotherapeutic agents. Thus, this study was established to speculate on the efficacy of Carva against cyclophosphamide (Cyclo)-provoked POF.
methodsA twenty-four mature female rats were randomly and equally allocated into four groups; normal group, Carva (15 mg/kg/day/orally/3 weeks) group, Cyclo (75 mg/kg/i.p/once weekly/3 weeks) group, and Carva + Cyclo group. Assessments of serum sex hormones, as well as ovarian oxidative stress-related pathways, along with histopathological alterations in ovary and uterine tissues, have been investigated. In addition, monitoring the rats' estrous cycle was performed via vaginal cytology.
resultsOur findings revealed that Carva ameliorated the disturbance of rats' estrous cycle, as well as loss of rats' body weight, and reproductive tract weight brought on by Cyclo. In addition, Carva administration modulated the disturbances in serum Anti-Mullerian hormone, estradiol, total estrogen, progesterone, follicle-stimulating hormone, and luteinizing hormone that resulted from Cyclo toxicity. The incidence of oxidative stress following Cyclo was significantly corrected by Carva, as indicated by a decline in ovarian malondialdehyde content and an increase in glutathione level. Carva effectively abrogated the increase in phosphorylated forms of protein kinase B (AKT), forkhead box protein O3a (FOXO3a), phosphoinositide 3-kinases (PI3K), and phosphatase and tensin homolog protein content in the ovarian tissue following Cyclo. Moreover, Carva ameliorated the structural changes of Cyclo in the ovarian and uterus tissues, and collagen condensation in the uterus. A marked preservation in the follicle count was recorded in the Cyclo + Carva group. The immunohistochemical findings revealed the hyper-expression of p-AKT along with activation of caspase 3 in the ovarian regions of Cyclo group, which is down-regulated by Carva.
conclusionHence, it could be concluded that Carva could preserve rat ovarian function from the degenerative impacts of Cyclo treatment by lessening the oxidative and apoptotic insult via regulating the PI3K/AKT/FOXO3a pathways in the ovarian tissues, along with successful attenuation of uterine fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.